# DCTH catalysts: DELCATH SYSTEMS, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/dcth/catalysts

> DELCATH SYSTEMS, INC. (DCTH) has 4 upcoming catalysts. The next is the melphalan/hds followed by consolidation treatment with trifluridine-tipiracil plus bevacizumab primary completion, December 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | DELCATH SYSTEMS, INC. |
| Ticker | DCTH (Nasdaq) |
| SEC CIK | 872912 |
| SIC | 3841 |
| SEC filings | https://sec-api.dev/companies/dcth |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 12, 2013 | [Hepzato (melphalan hydrochloride) complete response letter (CRL)](https://sec-api.dev/pdufa/melphalan) | DCTH |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22201848_2024_Orig1s000OtherActionLtrs.pdf%22)) |
| August 14, 2023 | [Hepzato (melphalan hydrochloride) FDA approval](https://sec-api.dev/pdufa/melphalan) | DCTH |  | completed, approved | "NDA201848 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20230814, review_priority STANDARD; sponsor_name DELCATH SYSTEMS INC; product HEPZATO (MELPHALAN HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA201848%22)) |
| December 2026 | [Melphalan/hds followed by consolidation treatment with trifluridine-tipiracil plus bevacizumab primary completion](https://sec-api.dev/pdufa/melphalan-hds-followed-by-consolidation-treatment-with-trifluridine-tipiracil-pl) | DCTH | Refractory Metastatic Colorectal Cancer | scheduled | "NCT06607458 (Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Delcath Systems Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06607458)) |
| Dec 2026 to Mar 2027 | [Melphalan/hds followed by consolidation treatment with trifluridine-tipiracil plus bevacizumab topline data readout](https://sec-api.dev/pdufa/melphalan-hds-followed-by-consolidation-treatment-with-trifluridine-tipiracil-pl) | DCTH | Refractory Metastatic Colorectal Cancer | scheduled | "NCT06607458 (Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Delcath Systems Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06607458)) |
| May 2029 | [Melphalan/hds followed by physician's choice of soc (eribulin, vinorelbine, or capecitabine) primary completion](https://sec-api.dev/pdufa/melphalan-hds-followed-by-physician-s-choice-of-soc-eribulin-vinorelbine-or-cape) | DCTH | Metastatic Breast Cancer in the Liver | scheduled | "NCT06875128 (Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05 (ESTIMATED); Lead Sponsor Delcath Systems Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06875128)) |
| May to Aug 2029 | [Melphalan/hds followed by physician's choice of soc (eribulin, vinorelbine, or capecitabine) topline data readout](https://sec-api.dev/pdufa/melphalan-hds-followed-by-physician-s-choice-of-soc-eribulin-vinorelbine-or-cape) | DCTH | Metastatic Breast Cancer in the Liver | scheduled | "NCT06875128 (Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05 (ESTIMATED); Lead Sponsor Delcath Systems Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06875128)) |

## Drugs

- [Hepzato (melphalan hydrochloride)](https://sec-api.dev/pdufa/melphalan): 
- [Melphalan/hds followed by consolidation treatment with trifluridine-tipiracil plus bevacizumab](https://sec-api.dev/pdufa/melphalan-hds-followed-by-consolidation-treatment-with-trifluridine-tipiracil-pl): Refractory Metastatic Colorectal Cancer
- [Melphalan/hds followed by physician's choice of soc (eribulin, vinorelbine, or capecitabine)](https://sec-api.dev/pdufa/melphalan-hds-followed-by-physician-s-choice-of-soc-eribulin-vinorelbine-or-cape): Metastatic Breast Cancer in the Liver

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/dcth/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "DCTH catalysts: DELCATH SYSTEMS, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/dcth/catalysts

```bibtex
@misc{secapidev_companies_dcth_catalysts_20261116,
  title        = {DCTH catalysts: DELCATH SYSTEMS, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/dcth/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_dcth_catalysts_20261116","title":"DCTH catalysts: DELCATH SYSTEMS, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/dcth/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
